Amgen Unveils Full Phase 2 Data on Monthly Obesity Drug MariTide, Highlighting Robust Weight Loss and Cardiometabolic Benefits at ADA 2024 Amgen has presented comprehensive results from the first part of its Phase 2 clinical trial investigating MariTide (formerly AMG…
Datroway Gains Accelerated FDA Approval for Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Datroway (datopotamab deruxtecan, also referred to as Dato-DXd) for the treatment of adult patients…
Merck’s WINREVAIR Achieves Primary Endpoint in Phase 3 HYPERION Trial for Pulmonary Arterial Hypertension in Newly Diagnosed Adults Merck, operating as MSD outside the United States and Canada, has announced a significant clinical milestone in its ongoing commitment to improving…
Novo Nordisk Secures EU CHMP Backing for Ozempic® Label Expansion in PAD, Reinforcing Semaglutide’s Role in Managing Type 2 Diabetes with Comorbidities Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)…
Exelixis Reports Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combo in Metastatic Colorectal Cancer Exelixis, has announced promising topline results from the STELLAR-303 phase 3 pivotal clinical trial, a major milestone in the development of its investigational therapy zanzalintinib.…
Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Sarclisa (isatuximab) in combination with…
Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its early-stage clinical development program evaluating NXT007, a next-generation investigational bispecific…
Novo Nordisk’s CagriSema Delivers Up to 22.7% Weight Loss in Obese or Overweight Adults, REDEFINE 1 Trial Results Published in NEJM In a significant advancement for the treatment of obesity and overweight, Novo Nordisk today announced the publication of pivotal…
Novo Nordisk Unveils Positive Phase 3b Results for Mim8 in Hemophilia A: Seamless Switch from Emicizumab Shows Safety, Efficacy, and High Patient Satisfaction Novo Nordisk presented new findings from its pivotal phase 3b FRONTIER5 clinical trial at the 2025 International…
CHMP Recommends Expanded Use of Bayer’s Nubeqa™ (Darolutamide) for Advanced Prostate Cancer Following Positive ARANOTE Trial Results The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending Bayer’s oral…
Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring the transformative potential of its investigational islet cell therapy, zimislecel…
FDA Approves Dupixent as the First and Only Targeted Therapy for Adults with Bullous Pemphigoid In a groundbreaking development for patients suffering from a rare and debilitating autoimmune skin disease, the U.S. Food and Drug Administration (FDA) has approved Dupixent…